December 21, 2010
Otsuka Pharmaceutical Co., Ltd.
Starting co-promotion of the anti-cancer agent
SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg (dasatinib)
Tokyo, Japan -- Bristol-Myers K.K. (Headquarters: Shinjuku-ku, Tokyo; President and CEO: Emmanuel Blin) and Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Taro Iwamoto) will start co-promotion activities on the sales of the anti-cancer agent "SPRYCEL Tablet 20mg and SPRYCEL Tablet 50mg" (dasatinib) in Japan on January 1st, 2011.
Information in this news release was current as of the original release date.